Risk factors related to pleural empyema after talc slurry pleurodesis
Authors:
- Paula Duarte D'AMbrosioPDPaula Duarte D'AMbrosio
- Pedro Henrique Xavier Nabuco de AraújoPAPedro Henrique Xavier Nabuco de Araújo
- Eserval Rocha JuniorEJEserval Rocha Junior
- Mauro Razuk FilhoMFMauro Razuk Filho
- Paulo Manuel Pêgo-FernandesPPPaulo Manuel Pêgo-Fernandes
- Ricardo Mingarini TerraRTRicardo Mingarini Terra
Open Access
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The American Association for Thoracic Surgery consensus guidelines for the management of empyemaThe Journal of Thoracic and Cardiovascular Surgery, 2017
- US Hospitalizations for Malignant Pleural EffusionsChest, 2017
- Cochrane corner: interventions for the management of malignant pleural effusionsThorax, 2016
- Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural EffusionRespiration, 2015
- Effectiveness and safety of outpatient pleurodesis in patients with recurrent malignant pleural effusion and low performance statusClinics, 2011
- U.K. Controlled Trial of Intrapleural Streptokinase for Pleural InfectionNew England Journal of Medicine, 2005
- Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural EffusionChest, 2005
- Pleurodesis for malignant pleural effusions2004
- Thoracoscopy Talc PoudrageChest, 2001
- Diseases of the pleura: the use of talc for pleurodesisCurrent Opinion in Pulmonary Medicine, 2000